Psychedelics in Psychiatry: Early Medical Adoption and Practice-of-Medicine Gray Zones
- April 10, 2026
- Kimberly Chew , Husch Blackwell LLP
- L. Alison McInnes , Mindful Health Solutions
Compass Pathways’ February 2026 announcement of successful Phase 3 results for COMP360 psilocybin in treatment-resistant depression, with an expected Q4 2026 new drug application submission, brings psychedelic therapy to the threshold of Food and Drug Administration (FDA) approval and clinical implementation. This transition from research to practice presents health care systems with unprecedented operational challenges: translating carefully controlled trial protocols into real-world treatment programs for medically complex patients who would have been excluded from pivotal trials. A 2026 analysis of psilocybin trial exclusion criteria found that cardiovascular disease, hepatic impairment, pregnancy, and medication interactions would exclude many real-world patients, highlighting the gap between trial populations and clinical practice.
ARTICLE TAGS
You must be logged in to access this content.